• 1
    Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-790.
  • 2
    Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419-425.
  • 3
    Maluf DG, Edwards EB, Kauffman HM. Utilization of extended donor criteria liver allograft: is the elevated risk of failure independent of the Model for End-Stage Liver Disease Score of the recipient? Transplantation 2006; 82: 1653-1657.
  • 4
    Blok JJ, Braat AE, Adam R, Burroughs AK, Putter H, Kooreman NG, et al.; for European Liver Intestine Transplant Association and Eurotransplant Liver Intestine Advisory Committee. Validation of the donor risk index in orthotopic liver transplantation within the Eurotransplant region. Liver Transpl 2012; 18: 112-119.
  • 5
    Spitzer AL, Lao OB, Dick AA, Bakthavatsalam R, Halldorson JB, Yeh MM, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 2010; 16: 874-884.
  • 6
    Briceño J, Padillo J, Rufián S, Solórzano G, Pera C. Assignment of steatotic livers by the Mayo Model for End-Stage Liver Disease. Transpl Int 2005; 18: 577-583.
  • 7
    Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology 2004; 230: 276-280.
  • 8
    Rana A, Hardy MA, Halazun KJ, Woodland DC, Ratner LE, Samstein B, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 2008; 8: 2537-2546.
  • 9
    Dutkowski P, Oberkofler CE, Slankamenac K, Puhan MA, Schadde E, Müllhaupt B, et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the Model for End-Stage Liver Disease era. Ann Surg 2011; 254: 745-753.
  • 10
    Halldorson JB, Bakthavatsalam R, Fix O, Reyes JD, Perkins JD. D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching. Am J Transplant 2009; 9: 318-326.
  • 11
    Vitale A, Ramirez Morales R, dalla Bona E, Scopelliti M, Zanus G, Neri D, et al. Donor-Model for End-Stage Liver Disease and donor-recipient matching in liver transplantation. Transplant Proc 2011; 43: 974-976.
  • 12
    Desai NM, Mange KC, Crawford MD, Abt PL, Frank AM, Markmann JW, et al. Predicting outcome after liver transplantation: utility of the Model for End-Stage Liver Disease and a newly derived discrimination function. Transplantation 2004; 77: 99-106.
  • 13
    Trotter JF, Osgood MJ. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA 2004; 291: 1871-1874.
  • 14
    Duarte IF, Stanley EG, Holmes E, Lindon JC, Gil AM, Tang H, et al. Metabolic assessment of human liver transplants from biopsy samples at the donor and recipient stages using high-resolution magic angle spinning 1H NMR spectroscopy. Anal Chem 2005; 77: 5570-5578.
  • 15
    Friedman BH, Wolf JH, Wang L, Putt ME, Shaked A, Christie JD, et al. Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transpl 2012; 18: 166-176.
  • 16
    de Jonge J, Kurian S, Shaked A, Reddy KR, Hancock W, Salomon DR, Olthoff KM. Unique early gene expression patterns in human adult-to-adult living donor liver grafts compared to deceased donor grafts. Am J Transplant 2009; 9: 758-772.